Collegium Pharmaceutical, Inc.
COLL · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $781M | $631M | +23.6% |
| Operating income | $180M | $170M | +5.7% |
| Net income | $62.9M | $69.2M | −9.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $216M | $209M | +3.3% |
| Operating income | $28.7M | $62.1M | −53.8% |
| Net income | $21.8M | $31.5M | −30.8% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Collegium's revenue in FY2025?
- $781M in FY2025 (Fiscal year ended Dec 31, 2025), +23.6% vs $631M a year earlier, per its 10-K filed Feb 2026.
- Was Collegium profitable in FY2025?
- Yes: net income was $62.9M and operating income $180M in FY2025.
- What was Collegium's revenue in Q3 2026?
- $216M (+3.3% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.